Literature DB >> 8738587

Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group.

J Harenberg1, P Roebruck, D L Heene.   

Abstract

In a multicenter, double-blind clinical trial in 1,968 inpatients 1 daily subcutaneous administration of LMW heparin plus 2 placebo injections or 3 x 5,000 IU unfractionated (UF) heparin was given for 10 (8-11) days. The primary end point was the incidence of proximal deep-vein thrombosis or pulmonary embolism. Patients were assessed during the study period for development of proximal deep-vein thrombosis by compression sonography at days 1 and 10 and for pulmonary embolism by scintigraphy in symptomatic patients. Aim of the study was to demonstrate the equivalence of both treatment regimens. A total of 1,968 patients were randomized to receive UF or LMW heparin. Of these, 378 patients were excluded during the study period, so that 780 patients on UF and 810 on LMW heparin were included in the efficacy analysis. Four primary end points were observed with UF and 6 with LMW heparin, demonstrating the equivalence of treatments (p = 0.012). Additionally, pulmonary embolism was suspected as the cause of death in 6 patients who died during the study (3 per treatment group). A higher frequency of death (n = 32) was observed in the LMW-heparin group (p = 0.02) particularly documented in a part of the centers. Safety analysis showed a higher frequency of local pruritus, local erythema and subcutaneous hematoma, a higher increase in plasma levels of triglycerides, total cholesterol, alanine aminotransferase and aspartate aminotransferase, and a decrease of antithrombin III in patients receiving UF heparin. A decrease in platelet count (values ranging between 40,000 and 80,000/microliter) was observed in 4 patients with UF and in none with LMW heparin. No severe thrombocytopenia was observed. Subcutaneous LMW heparin is as effective as UF heparin for prophylaxis of thromboembolism in bedridden, hospitalized medical patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8738587     DOI: 10.1159/000217198

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  29 in total

Review 1.  Venous thromboembolism prophylaxis with unfractionated heparin in the hospitalized medical patient: the case for thrice daily over twice daily dosing.

Authors:  Charles E Mahan; Mario Pini; Alex C Spyropoulos
Journal:  Intern Emerg Med       Date:  2010-02-23       Impact factor: 3.397

Review 2.  Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients.

Authors:  Ana T Rocha; Edison F Paiva; Arnaldo Lichtenstein; Rodolfo Milani; Cyrillo Filho Cavalheiro; Francisco H Maffei
Journal:  Vasc Health Risk Manag       Date:  2007

3.  Incidence of drug-induced liver injury in medical inpatients.

Authors:  Yvonne Meier; Marzia Cavallaro; Malgorzata Roos; Christiane Pauli-Magnus; Gerd Folkers; Peter J Meier; Karin Fattinger
Journal:  Eur J Clin Pharmacol       Date:  2005-02-23       Impact factor: 2.953

Review 4.  Formulary management of low molecular weight heparins.

Authors:  W E Wade; B C Martin; J A Kotzan; W J Spruill; M A Chisoholm; M Perri
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

Review 5.  Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.

Authors:  R Davis; D Faulds
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

6.  Extended pharmacologic thromboprophylaxis in oncologic liver surgery is safe and effective.

Authors:  B J Kim; R W Day; C H Davis; N Narula; M H Kroll; C W D Tzeng; T A Aloia
Journal:  J Thromb Haemost       Date:  2017-09-27       Impact factor: 5.824

Review 7.  Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation.

Authors:  Lara A Kahale; Maram B Hakoum; Ibrahim G Tsolakian; Charbel F Matar; Maddalena Barba; Victor E D Yosuico; Irene Terrenato; Francesca Sperati; Holger Schünemann; Elie A Akl
Journal:  Cochrane Database Syst Rev       Date:  2017-12-29

Review 8.  Deep venous thrombosis prophylaxis in patients with heart disease.

Authors:  B K Shively
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 2.931

Review 9.  Venous thromboembolism prophylaxis in medically ill patients: a mixed treatment comparison meta-analysis.

Authors:  Majed S Al Yami; Matthew A Silva; Jennifer L Donovan; Abir O Kanaan
Journal:  J Thromb Thrombolysis       Date:  2018-01       Impact factor: 2.300

Review 10.  Nadroparin for the prevention of venous thromboembolism in nonsurgical patients: a systematic review and meta-analysis.

Authors:  Walter Ageno; Jacqueline Bosch; Michel Cucherat; John W Eikelboom
Journal:  J Thromb Thrombolysis       Date:  2016-07       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.